BioCentury
ARTICLE | Company News

Xoma infectious news

October 10, 2011 7:00 AM UTC

Xoma received a five-year contract worth up to $28 million from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop antitoxins to treat Type C and D botulism poisoning. Xoma has received about $120 million in contracts from NIAID for biodefense-related product development. ...